|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future显示文摘The problems associated with the pharmacological treatment of the later stages of Parkinson’s disease(PD)remain those seen over many years.These centre on a loss of drug effect(‘wearing off’)with disease progression,the occurrence of dyskinesia,notably with L-dopa use and the appearance of non-motor symptoms that are largely refractory to dopaminergic medication.Treatment strategies in late PD have been dominated by the use of drug combinations and the subtle manipulation of drug dosage.However,change is occurring as the understanding of the basis of motor complications and fluctuations and non-motor symptoms improves.New pharmacological options are expanding with the advent of longer acting versions of existing dopaminergic drugs,new drug delivery systems and the introduction of non-dopaminergic agents able to manipulate motor function both within the basal ganglia and in other brain regions.Non-dopaminergic agents are also being investigated for the treatment of dyskinesia and for the relief of non-motor symptoms.However,while therapy continues to improve,the treatment of late stage PD remains problematic with non-motor symptoms dominating the unmet need in this patient group. | Peter Jenner | 2015 | Translational Neurodegeneration2015，4，1： | 8 |
| 2 | Understanding cell death in parkinson’s disease显示文摘 | Peter Jenner C. Warren Olanow | 1998 | Ann Neurol1998，，1： | 2 |
| 3 | Oxidative stress and the pathogenesis of Parkinson's disease显示文摘 | Peter Jenner DSc FRPharms C Warren Olanow | 1996 | Neurology December1996，47，3： | 1 |
| 4 | Parkinson’s disease, pesticides and mitochondrial dysfunction显示文摘 | Peter Jenner | 2001 | Trends in Neurosciences2001，，5： | 1 |
| 5 | Sulphite enhances peroxynitrite-dependent α 1 -antiproteinase inactivation. A mechanism of lung injury by sulphur dioxide?显示文摘 | Marianne Reist Peter Jenner Barry Halliwell | 1998 | FEBS Letters1998，，2： | 1 |
| 6 | Proteasome inhibition causes nigral degeneration with inclusion bodies in rats显示文摘 | Kevin St. P. McNaught Lars M. Bj?rklund Roger Belizaire Ole Isacson Peter Jenner C. Warren Olanow | 2002 | Neuroreport2002，，11： | 1 |
| 7 | A2A antagonists as novel non-dopaminergid therapy for motor dysfuction in PD 显示文摘 | Peter Jenner | 2003 | Neurology2003，61，6： | 1 |
| 8 | Altered Proteasomal Function in Sporadic Parkinson’s Disease显示文摘 | Kevin St. P. McNaught Roger Belizaire Ole Isacson Peter Jenner C.Warren Olanow | 2002 | Experimental Neurology2002，，1： | 1 |
| 9 | No evidence for increased oxidative damage to lipids,proteins, or DNA in Huntington's disease 显示文摘 | Alam Zafar I Halliwell Barry Jenner Peter | 2000 | J Neurochem2000，75，2： | 1 |
| 10 | Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease显示文摘 | Jacques J. Genest Sarah S. Martin-Munley Judith R. McNamara Jose M. Ordovas Jennifer Jenner Richard H. Myers Steven R. Silberman Peter W.F. Wilson Deeb N. Salem Ernst J. Schaefer | 1992 | Circulation1992，，6： | 1 |
| 11 | Effect and Mechanism of Acupuncture on Alzheimer’s Disease显示文摘 | Bai-Yun Zeng Sarah Salvage Peter Jenner | 2013 | International Review of Neurobiology2013，，： | 1 |
| 12 | No evidence for increased oxidative damage to lipids, proteins, or DNA in hun tingtoffs disease显示文摘 | Zafar I Alam Barry Halliwell Peter Jenner | 2000 | Jn euroehem2000，75，2： | 1 |
| 13 | Uptake and metabolism of epicatechin and its access to the brain after oral ingestion显示文摘 | Manal M Abd El Mohsen Gunter Kuhnle Andreas R Rechner Hagen Schroeter Sarah Rose Peter Jenner Catherine A Rice-Evans | 2002 | Free Radical Biology and Medicine2002，，12： | 1 |
| 14 | Oxidative stress and the pathogenesis of Parkinson′s disease显示文摘 | Peter Jenner FR Pharms C Warren Olanow | 1996 | Neurology December1996，47，3： | 1 |
| 15 | Another look at social innovation:From community-For community显示文摘Social innovation(SI)continues to raise interest among scholars and policymakers,as a potential panacea for social disenfranchisement and civic dysfunction.What is troubling is diverse perspectives of SI abound,creating inconsistencies in methodological approaches which confound theory development.This paper clarifies that discussion by considering the locus of initiation and locus of benefit as informing characteristics that differentiate grounded social innovation from other types of well-recognized socially beneficent endeavors.The notion of‘from community e for community’is presented to aid understanding of the unique nature of authentically grounded social innovation.This paper is significant as it presents a practical approach to help researchers and practitioners consider where opportunities for targeted policy support,institutional involvement,and agency action can aid community development and wellbeing. | Lisa J.Daniel Peter Jenner | 2022 | International Journal of Innovation Studies2022，6，2： | 0 |
| 16 | Why do‘OFF’periods still occur during continuous drug delivery in Parkinson’s disease?显示文摘Continuous drug delivery(CDD)is used in moderately advanced and late-stage Parkinson’s disease(PD)to control motor and non-motor fluctuations(‘OFF’periods).Transdermal rotigotine is indicated for early fluctuations,while subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel are utilised in advanced PD.All three strategies are considered examples of continuous dopaminergic stimulation achieved through CDD.A central premise of the CDD is to achieve stable control of the parkinsonian motor and non-motor states and avoid emergence of‘OFF’periods.However,data suggest that despite their efficacy in reducing the number and duration of‘OFF’periods,these strategies still do not prevent‘OFF’periods in the middle to late stages of PD,thus contradicting the widely held concepts of continuous drug delivery and continuous dopaminergic stimulation.Why these emergent‘OFF’periods still occur is unknown.In this review,we analyse the potential reasons for their persistence.The contribution of drug-and device-related involvement,and the problems related to site-specific drug delivery are analysed.We propose that changes in dopaminergic and non-dopaminergic mechanisms in the basal ganglia might render these persistent‘OFF’periods unresponsive to dopaminergic therapy delivered via CDD. | Silvia Rota Daniele Urso Daniel J.van Wamelen Valentina Leta Iro Boura Per Odin Alberto J.Espay Peter Jenner K.Ray Chaudhuri | 2022 | Translational Neurodegeneration2022，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员